Possible association of a cholecystokinin promoter variant to schizophrenia

American Journal of Medical Genetics - Neuropsychiatric Genetics

Volumn 114, Issue 5, 2002, Pages 479-482

  Wang, Zhewu ^a   Wassink, Thomas ^b   Andreasen, Nancy C ^b   Crowe, Raymond R ^b  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF IOWA   (United States)

Author keywords

Case control association; Family based association; Haplo type relative risk (HRR); Transmission disequilibrium test (TDT)

Indexed keywords

CHOLECYSTOKININ;

ALLELE; ARTICLE; CASE CONTROL STUDY; CONTROLLED STUDY; ETHNIC DIFFERENCE; FAMILY STUDY; GENE FREQUENCY; GENE LINKAGE DISEQUILIBRIUM; GENETIC ASSOCIATION; GENETIC RISK; GENETIC VARIABILITY; HAPLOTYPE; HUMAN; INHERITANCE; MAJOR CLINICAL STUDY; NUCLEIC ACID BASE SUBSTITUTION; PRIORITY JOURNAL; PROMOTER REGION; SAMPLE SIZE; SCHIZOPHRENIA; SYMPTOM;

ALLELES; CHOLECYSTOKININ; DNA; DNA MUTATIONAL ANALYSIS; GENE FREQUENCY; GENOTYPE; HUMANS; LINKAGE DISEQUILIBRIUM; PHENOTYPE; POINT MUTATION; POLYMORPHISM, SINGLE-STRANDED CONFORMATIONAL; PROMOTER REGIONS (GENETICS); SCHIZOPHRENIA;

EID: 0037043049     PISSN: 15524841     EISSN: 1552485X     Source Type: Journal    
DOI: 10.1002/ajmg.10408     Document Type: Article

References (32)

1. Abnormal cholecystokinin mRNA levels in entorhinal cortex of schizophrenics
2. Concentration of cholecystokinin in cerebrospinal fluid is decreased in psychosis: Relationship to symptoms and drug response
3. Linked polymorphisms upstream of exons 1 and 2 of the human cholecystokinin gene are not associated with schizophrenia or bipolar disorder
4. Cholecystokinin potentiates dopamine-mediated behavior: Evidence for modulation specific to a site of existence
5. Reduced high affinity cholecystokinin binding in hippocampus and frontal cortex of schizophrenia patients
6. Reduced cholecystokinin-like and somatostatin-like immunoreactivity in limbic lobe is associated with negative symptoms of schizophrenia
7. Cholecystokinin, dopamine and schizophrenia
8. Confirming unexpressed genotypes for schizophrenia: Risks in the offspring of Fischer's Danish identical and fraternal discordant twins
9. 36 to T polymorphism in the human cholecystokinin gene promoter
10. Evidence for coexistence of dopamine and CCK in mesolimbic neurons
11. Promoter-specific activation of RNA polymerase II transcription by Sp1
12. The genetics of schizophrenia: A current genetic-epidemiologic perspective
13. Schizophrenic illness in the families of schizophrenic adoptees: Findings from the Danish national sample
14. A rapid non-enzymatic method for the preparation of HMW DNA from blood for RFLP studies
15. Cholecystokinin, beta endorphin and vasoactive intestinal peptide in peripheral blood mononuclear cells of drug-naive schizophrenic patients treated with haloperidol compared to healthy controls
16. Origin of the cholecystokinin-containing fibers in the rat caudatoputamen
17. Transcriptional regulation of the human cholecystokinin gene: Composite action of upstream stimulatory factor, Sp1 and members of the CREB/ATF-AP-1 family of transcription factors
18. Neuropeptides in Alzheimer's disease, depression and schizophrenia. A post mortem analysis of vasoactive intestinal peptide and cholecystokinin in cerebral cortex
19. Association of transforming growth-factor alpha gene polymorphisms with nonsyndromic cleft palate only (CPO)
20. Different populations of GABAergic neurons in the visual cortex and hippocampus of cat contain somatostatin- or cholecystokinin-immunoreactive material
21. Transmission test for linkage disequilibrium: The insulin gene region and insulin-dependent diabetes mellitus (IDDM)
22. Novel polymorphisms in the promoter and coding regions of the human cholecystokinin B receptor gene: An association analysis with schizophrenia
23. Novel polymorphisms of the human cholecystokinin A receptor gene: An association analysis with schizophrenia
24. Structure of human cholecystokinin gene and its chromosomal location
25. Neural cholecystokinin and schizophrenia: Pathogenetic and therapeutic studies
26. A haplotype-based 'haplotype relative risk' approach to detecting allelic associations
27. Reduced cholecystokinin immunoreactivity in cerebrospinal fluid of patients with psychiatric disorders
28. Cholecystokinin messenger RNA deficit in frontal and temporal cerebral cortex in schizophrenia
29. Possible association of a cholecystokinin promoter polymorphism with panic disorder
30. The CCK-A receptor gene possibly associated with auditory hallucinations in schizophrenia